Common Contracts

5 similar Significant Subsidiaries contracts by CVS HEALTH Corp, CVS Caremark Corp

CVS HEALTH CORPORATION $1,500,000,000 5.000% Senior Notes due 2026 $1,500,000,000 5.125% Senior Notes due 2030 $1,750,000,000 5.250% Senior Notes due 2033 $1,250,000,000 5.625% Senior Notes due 2053 Underwriting Agreement
Significant Subsidiaries • February 15th, 2023 • CVS HEALTH Corp • Retail-drug stores and proprietary stores • New York

CVS Health Corporation, a Delaware corporation (the “Company”), proposes to issue and sell $1,500,000,000 aggregate principal amount of its 5.000% Senior Notes due 2026 (the “2026 Notes”), $1,500,000,000 aggregate principal amount of its 5.125% Senior Notes due 2030 (the “2030 Notes”), $1,750,000,000 aggregate principal amount of its 5.250% Senior Notes due 2033 (the “2033 Notes”) and $1,250,000,000 aggregate principal amount of its 5.625% Senior Notes due 2053 (the “2053 Notes” and together with the 2026 Notes, the 2030 Notes and the 2033 Notes, the “Notes”) to the several underwriters named on Schedule I hereto (the “Underwriters”), for which BofA Securities, Inc., Barclays Capital Inc., and J.P. Morgan Securities LLC are acting as representatives (the “Representatives”). The Notes will (a) have terms and provisions which are summarized in the Disclosure Package as of the Applicable Time and the Prospectus dated as of the date hereof (each as defined in Section 1(a) hereof) and (b) b

AutoNDA by SimpleDocs
CVS HEALTH CORPORATION $1,000,000,000 2.125% Senior Notes due 2031 Underwriting Agreement
Significant Subsidiaries • August 11th, 2021 • CVS HEALTH Corp • Retail-drug stores and proprietary stores • New York

CVS Health Corporation, a Delaware corporation (the “Company”), proposes to issue and sell $1,000,000,000 aggregate principal amount of its 2.125% Senior Notes due 2031 (the “Notes”) to the several underwriters named on Schedule I hereto (the “Underwriters”), for which Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC are acting as representatives (the “Representatives”). The Notes will (a) have terms and provisions which are summarized in the Disclosure Package as of the Applicable Time and the Prospectus dated as of the date hereof (each as defined in Section 1(a) hereof) and (b) be issued pursuant to an Indenture dated as of August 15, 2006 (the “Indenture”) between the Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.), as trustee (the “Trustee”). This agreement (this “Agreement”) is to confirm the agreement concerning the purchase of the Notes from the Company by the Underwriters.

CVS HEALTH CORPORATION $1,500,000,000 1.300% Senior Notes due 2027 $1,250,000,000 1.750% Senior Notes due 2030 $1,250,000,000 2.700% Senior Notes due 2040 Underwriting Agreement
Significant Subsidiaries • August 14th, 2020 • CVS HEALTH Corp • Retail-drug stores and proprietary stores • New York

CVS Health Corporation, a Delaware corporation (the “Company”), proposes to issue and sell $1,500,000,000 aggregate principal amount of its 1.300% Senior Notes due 2027 (the “2027 Notes”), $1,250,000,000 aggregate principal amount of its 1.750% Senior Notes due 2030 (the “2030 Notes”) and $1,250,000,000 aggregate principal amount of its 2.700% Senior Notes due 2040 (the “2040 Notes” and, together with the 2027 Notes and 2030 Notes, the “Notes”) to the several underwriters named on Schedule I hereto (the “Underwriters”), for which Barclays Capital Inc., BofA Securities, Inc. and Goldman Sachs & Co. LLC are acting as representatives (the “Representatives”). The Notes will (a) have terms and provisions which are summarized in the Disclosure Package as of the Applicable Time and the Prospectus dated as of the date hereof (each as defined in Section 1(a) hereof) and (b) be issued pursuant to an Indenture dated as of August 15, 2006 (the “Indenture”) between the Company and The Bank of New Y

CVS HEALTH CORPORATION $750,000,000 3.625% Senior Notes due 2027 $1,500,000,000 3.750% Senior Notes due 2030 $1,000,000,000 4.125% Senior Notes due 2040 $750,000,000 4.250% Senior Notes due 2050 Underwriting Agreement
Significant Subsidiaries • March 31st, 2020 • CVS HEALTH Corp • Retail-drug stores and proprietary stores • New York

CVS Health Corporation, a Delaware corporation (the “Company”), proposes to issue and sell $750,000,000 aggregate principal amount of its 3.625% Senior Notes due 2027 (the “2027 Notes”), $1,500,000,000 aggregate principal amount of its 3.750% Senior Notes due 2030 (the “2030 Notes”), $1,000,000,000 aggregate principal amount of its 4.125% Senior Notes due 2040 (the “2040 Notes”) and $750,000,000 aggregate principal amount of its 4.250% Senior Notes due 2050 (the “2050 Notes” and, together with the 2027 Notes, 2030 Notes and 2040 Notes, the “Notes”) to the several underwriters named on Schedule I hereto (the “Underwriters”), for which Barclays Capital Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities are acting as representatives (the “Representatives”). The Notes will (a) have terms and provisions which are summarized in the Disclosure Package as of the Applicable Time and the Prospectus dated as of the date hereof (each as defined in Section 1(a) hereof) and (b) be issued pursu

CVS CAREMARK CORPORATION $1,250,000,000 2.75% Senior Notes due 2022 Underwriting Agreement
Significant Subsidiaries • November 29th, 2012 • CVS Caremark Corp • Retail-drug stores and proprietary stores • New York

CVS Caremark Corporation, a Delaware corporation (the “Company”), proposes to issue and sell $1,250,000,000 aggregate principal amount of its 2.75% Senior Notes due 2022 (the “Notes”) to the several underwriters named on Schedule I hereto (the “Underwriters”), for which Barclays Capital Inc., Wells Fargo Securities, LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, BNY Mellon Capital Markets, LLC and J.P. Morgan Securities LLC are acting as representatives (the “Representatives”). The Notes will (i) have terms and provisions which are summarized in the Disclosure Package as of the Applicable Time and the Prospectus dated as of the date hereof (each as defined in Section 1(a) hereof) and (ii) be issued pursuant to an Indenture dated as of August 15, 2006 (the “Indenture”) between the Company and The Bank of New York Trust Company, N.A., as trustee (the “Trustee”). This agreement (this “Agreement”) is to confirm the agreement concerning the purchase of the Notes from the Company b

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!